Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis
Status:
Unknown status
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In
China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe
economic and social burden, as well as the potential risk of developing other chronic
diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to
explore the classification and treatment strategies of chronic rhinitis in order to improve
the health level of Chinese people.
Phase:
N/A
Details
Lead Sponsor:
Beijing Tongren Hospital
Collaborators:
Beijing Institute of Otolaryngology Shanghai Johnson & Johnson Pharmaceuticals, Ltd.